Femasys announces peer-reviewed publication of positive safety and efficacy results from fembloc® permanent birth control clinical trials

--positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- atlanta, feb. 25, 2025 (globe newswire) -- femasys inc., (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its initial clinical trials of fembloc® permanent birth control in the journal of gynecology & reproductive medicine (jgrm) , a leading peer-reviewed journal covering gynecology and reproductive medicine.
FEMY Ratings Summary
FEMY Quant Ranking